AvantorAVTR
AVTR
About: Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Employees: 14,500
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more capital invested
Capital invested by funds: $13.8B [Q2] → $17.4B (+$3.6B) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 10 [Q2] → 12 (+2) [Q3]
20% more repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 168
3.2% more ownership
Funds ownership: 96.18% [Q2] → 99.37% (+3.2%) [Q3]
1% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 79
0% more funds holding
Funds holding: 500 [Q2] → 501 (+1) [Q3]
69% less call options, than puts
Call options by funds: $75.9M | Put options by funds: $245M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
16%
upside
Avg. target
$28
32%
upside
High target
$34
58%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Brandon Couillard 22% 1-year accuracy 4 / 18 met price target | 30%upside $28 | Overweight Maintained | 28 Oct 2024 |
Baird Catherine Schulte 24% 1-year accuracy 5 / 21 met price target | 21%upside $26 | Outperform Maintained | 28 Oct 2024 |
Barclays Luke Sergott 25% 1-year accuracy 12 / 48 met price target | 16%upside $25 | Overweight Maintained | 25 Oct 2024 |
UBS Daniel Brennan 33% 1-year accuracy 2 / 6 met price target | 35%upside $29 | Buy Maintained | 8 Oct 2024 |
RBC Capital Conor McNamara 26% 1-year accuracy 10 / 39 met price target | 58%upside $34 | Outperform Reiterated | 26 Sept 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
Avantor: Durable FCF Generator Trading For Cheap
Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor's leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company's capital structure and return value to shareholders.
Positive
Zacks Investment Research
2 weeks ago
MD or AVTR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Avantor, Inc. (AVTR). But which of these two companies is the best option for those looking for undervalued stocks?
Neutral
PRNewsWire
1 month ago
Avantor® to Participate in the 7th Annual Evercore ISI HealthCONx Conference
RADNOR, Pa. , Nov. 20, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Tuesday, December 3, at 9:10 a.m.
Neutral
Business Wire
1 month ago
Avantor to Distribute Quantum-Si's Next-Generation Protein Sequencing™ Technology
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in t.
Neutral
PRNewsWire
1 month ago
Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science's Biggest Challenges
RADNOR, Pa. , Nov. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center.
Neutral
PRNewsWire
1 month ago
Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors
RADNOR, Pa. , Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D.
Positive
Zacks Investment Research
1 month ago
Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down
Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance.
Neutral
Seeking Alpha
2 months ago
Avantor Inc. (AVTR) Q3 2024 Earnings Call Transcript
Avantor Inc. (NYSE:AVTR ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President and Chief Executive Officer Brent Jones - Executive Vice President and Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Douglas Schenkel - Wolfe Research Tycho Peterson - Jefferies Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Daniel Leonard - UBS Conor McNamara - RBC Capital Markets Daniel Arias - Stifel Rachel Vatnsdal - JP Morgan Luke Sergott - Barclays Tejas Savant - Morgan Stanley Operator Good morning. My name is Emily, and I will be your conference operator today.
Positive
Zacks Investment Research
2 months ago
Avantor (AVTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
2 months ago
Avantor, Inc. (AVTR) Beats Q3 Earnings Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago.
Charts implemented using Lightweight Charts™